This pharmaceutical stock rose slightly on the 9th, and at the beginning of the year, it was investigated by more than 100 institutions for an insomnia drug

News on January 9, as of 10:05, Jingxin Pharmaceutical rose slightly by nearly 1%, with a quotation of 13.
03 yuan, a turnover of 30.
27 million, a turnover rate of 0.
35%, a price-to-earnings (TTM) of 17.
35, and a total market value of 11.
219 billion
.
On the news, Jingxin Pharmaceutical replied to investors on the investor interactive platform on January 6 that the pre-disclosure time of the company's 2022 annual report is March 30
, 2023.
If didacinib is successfully listed, it will first be sold and promoted
in China.
Dedacinib is a potential variety for the treatment of insomnia disorder, according to reports, compared with the traditional GABA receptor complete agonist, the drug has obvious advantages
in dyskinesia, sequelae effects, tolerance, ethanol interaction, body dependence, memory impairment and other adverse reactions.
Jingxin Pharmaceutical completed the phase III clinical trial of the drug in November 2021, reached the primary and secondary endpoints, and submitted a marketing application
to the Food and Drug Administration in March 2022.
Insomnia disorders are common in adults, with the acceleration of the pace of modern life, the increase of various stresses, the prevalence of insomnia is gradually increasing, according to the survey data of the "2021 Exercise and Sleep White Paper" released by the Chinese Sleep Research Association, more than 300 million people have sleep disorders
in 2021.
Other data show that in the past three years, nearly 70 million new patients with depression, 90 million people with anxiety disorders, and 100 million people with insomnia disorders
have occurred in the world.
The large patient population of insomnia disorders will drive the growth
of the insomnia drugs market.
According to data, the domestic insomnia drug (excluding traditional Chinese medicine) market size has increased from 9.
84 billion yuan to 11.
7 billion yuan in 2020, exceeding the 10 billion yuan mark, and is expected to exceed 13 billion yuan
in 2023.
Recently, the listing progress of didacinib has attracted the attention
of institutions and investors.
Jingxin Pharmaceutical has said in an institutional survey that dassinib is currently advancing at a normal pace, and the listing expectation has not changed
.
At present, most of the mainstream drugs for the treatment of insomnia in the market have been collected, and it is expected that the sales of didacinide after the listing are expected to be based on the scale before the mainstream drug collection, but after the drug is launched, the company will actively promote academic promotion and promote the volume
of drugs.
Jingxin Pharmaceutical replied to investors on the interactive platform on January 3 that didacinib is still in the comprehensive review stage, and the company will continue to pay attention to the approval dynamics and announce the relevant approval progress
in accordance with the information disclosure requirements.
According to data from Oriental Wealth Choice, on January 4, 176 institutions investigated Jingxin Pharmaceutical and paid attention to the situation of
didacinib again.
In this regard, Jingxin Pharmaceutical said that in the future, the pricing strategy of didacinide after the listing, the company will consider from several aspects: pharmacoeconomic perspective; supply chain perspective; market competitive environment; the patient's ability to pay, and so on
.
A relatively reasonable price
will be formulated after comprehensive consideration of various factors.
Also on January 6, the company said on the interactive platform that Jingchangle (Bacillus licheniformis live bacteria capsule) is indicated for acute and chronic enteritis and diarrhea caused by bacteria or fungi, and can also be used for the prevention and treatment
of gastrointestinal dysbacteriosis caused by other causes.
Neither the company nor its subsidiaries have the drug montmorillonite
.
According to the third quarter report of 2022, Jingxin Pharmaceutical achieved main revenue of 2.
80 billion yuan, a year-on-year increase of 9.
29%; net profit attributable to owners was RMB472 million, up 7.
45% year-on-year; Non-net profit was RMB447 million, up 15.
98% year-on-year; Among them, in the third quarter of 2022, the company's main revenue in a single quarter was 927 million yuan, a year-on-year increase of 11.
01%; The net profit attributable to owners in a single quarter was 175 million yuan, a year-on-year increase of 9.
66%; Quarterly non-net profit was RMB172 million, up 16.
46%
year-on-year.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.